EyeSouth Partners has partnered with Retina and Vitreous of Texas in Houston

News
Article

EyeSouth Partners has partnered with Retina and Vitreous of Texas, a retina-only practice in Houston, Texas. The company’s current network encompasses 38 practices and over 300 doctors who deliver medical and surgical eye care services across more than 180 locations.

©flashmovie  / Adobe.Stock.com

The company’s current network encompasses 38 practices and over 300 doctors who deliver medical and surgical eye care services across more than 180 locations. (Image Credit: ©flashmovie - Adobe.Stock.com)

EyeSouth Partners has partnered with Retina and Vitreous of Texas, a retina-only practice in Houston, Texas. This marks EyeSouth’s thirty-eighth overall affiliation and the network’s first retina-only affiliation in the state of Texas.

EyeSouth is an eye care-focused management services organization backed by Olympus Partners. The company’s current network encompasses 38 practices and over 300 doctors who deliver medical and surgical eye care services across more than 180 locations. This includes 19 surgery centers strategically situated throughout Georgia, Texas, Louisiana, Florida, Tennessee, Ohio, Kentucky, Pennsylvania, Alabama, Illinois, North Carolina, and South Carolina.

Retina and Vitreous of Texas has been serving the greater Houston market for over 25 years, been involved in upwards of 180 medical publications, and developed a nationally-renowned fellowship program since it was established in 1997. Today, the practice is led by a team of 6 board-certified, fellowship-trained physicians who are recognized for their patient care as well as the teaching and training of future vitreoretinal surgeons.

Joseph Khawly, MD, FACS shared his excitement for this partnership in the news release, saying “RVT is thrilled to be EyeSouth’s first retina-only focused partner in the state of Texas. We look forward to working with the EyeSouth family of practices in Houston and expanding our presence throughout this great city and beyond!”

Emmanuel Chang, MD, PhD, FACS echoed these sentiments in his statement, “We are excited to partner with EyeSouth in expanding what RVT has built; a legacy on providing the best personalized patient-centered retinal care in Houston and offering leading medical and surgical therapies for vitreoretinal diseases. This affiliation will allow RVT to further expand what our trademark values are: quality, integrity, and personalized attentive medicine. It is our relentless focus to provide the very best for our patients, restore sight, expand innovative clinical research, and help reshape the future of vitreoretinal care.”

“We couldn’t be more excited to have such a reputable retina-only practice join us, especially in such a high-growth market like Houston,” said Dr. Atul Sharma, Georgia Retina vitreoretinal specialist and EyeSouth Board Member. “It’s clear that the mission at RVT of providing premier vitreoretinal care permeates through the entire practice, and we can’t wait to see how our partnership helps strengthen that mission in the future.”

To learn more about a partnership with EyeSouth Partners, visit www.eyesouthpartners.com or contact Chris O’Dekirk, VP of M&A and Business Development, chris.odekirk@eyesouthpartners.com.

Reference:
  1. EyeSouth Partners Affiliates with Retina and Vitreous of Texas, Representing Its 38th Affiliation and First Retina Practice in Texas. September 5, 2023. Accessed September 5, 2023. https://www.businesswire.com/news/home/20230905912404/en/EyeSouth-Partners-Affiliates-with-Retina-and-Vitreous-of-Texas-Representing-Its-38th-Affiliation-and-First-Retina-Practice-in-Texas
Recent Videos
WIO 2024: An educator's perspective on shattering glass ceilings in ophthalmology
Hannah Chiu, MD, FRCSC, highlights some of the early benefits of an AI-operated telephone call system for postoperative patient care at WIO 2024
Retinal Inner Layer Disorganization and OCT in Uveitic Macular Edema: Insights from Dr. Amitha Domalpally
ARVO 2024: Study Reveals Faricimab's Potential for Extended Dosing in nAMD
© 2024 MJH Life Sciences

All rights reserved.